BlossomHill Therapeutics, Inc.(BLSM)

Biotechnology · San Diego, CA

$17.29-2.65 (-13.29%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T22:35:57.342Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:35:57.342Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 502,813,256
Total debt · period ending 2026-06-30: 23,371,000
Cash · period ending 2026-06-30: 95,376,000
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BLSM EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

BLSM Competitors' EV/EBITDA Ratio

BLSM

BlossomHill Therapeutics, Inc.

Current

Market Cap

$502.81M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLO

Allogene Therapeutics, Inc.

vs BLSM

Market Cap

$503.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBIO

Crescent Biopharma, Inc.

vs BLSM

Market Cap

$504.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TCMD

Tactile Systems Technology, Inc.

vs BLSM

Market Cap

$500.52M

EV/EBITDA Ratio

10.66x

TTM Avg

15.18x

3Y Avg

13.32x

5Y Avg

38.43x

MASS

908 Devices Inc.

vs BLSM

Market Cap

$505.87M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OCS

Oculis Holding AG

vs BLSM

Market Cap

$498.52M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs BLSM

Market Cap

$516.76M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs BLSM

Market Cap

$519.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EOLS

Evolus, Inc.

vs BLSM

Market Cap

$486.01M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBYI

Puma Biotechnology, Inc.

vs BLSM

Market Cap

$483.54M

EV/EBITDA Ratio

10.41x

TTM Avg

7.79x

3Y Avg

5.90x

5Y Avg

5.85x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
BlossomHill Therapeutics, Inc. (BLSM)	$502.81M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$503.93M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$504.04M	N/A	N/A	N/A	N/A
Tactile Systems Technology, Inc. (TCMD)vs ›	$500.52M	10.66x	15.18x	13.32x	38.43x
908 Devices Inc. (MASS)vs ›	$505.87M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$498.52M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$486.01M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$483.54M	10.41x	7.79x	5.90x	5.85x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics